Cellular therapies for rheumatic disease - PubMed
5 hours ago
- #CAR-T
- #cellular-therapies
- #rheumatic-disease
- Cellular therapies, especially CAR-modified lymphocytes, are being considered for autoimmune rheumatic diseases like SLE, IIM, and SSc.
- Recent studies show CD19-directed CAR T cells can induce deep B-cell depletion and drug-free remission in refractory SLE, with promising results in SSc and IIM.
- These therapies come with distinctive toxicity patterns, including low-grade CRS, rare ICANS, and organ-specific LICATS.
- Mechanistic 'immune reset' includes type I IFN pathway suppression and naïve-skewed B-cell repopulation.
- Emerging platforms include allogeneic CARs, γδ-CAR, CAR-NK, RNA CARs, and T cell engagers.
- Cellular therapies are transformative for severe, refractory lupus and autoimmune rheumatic diseases but require disciplined trial design and long-term safety surveillance.